Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab in Treating Patients With Post-Transplant Lymphoproliferative Disorder

Inclusion Criteria: * Histologically confirmed post-transplant lymphoproliferative disorder (PTLD) of 1 of the following stages: * Stage III or IV * Localized (not amenable to localized radiotherapy or excision) * Recurrent * The following histologies\* are eligible: * Polyclonal PTLD * Monoclonal PTLD * Diffuse large B-cell non-Hodgkin's lymphoma (NHL) * Lymphoplasmacytic NHL * Burkitt/Burkitt-like NHL * Must not have completely responded during OR progressed after prior rituximab with or without chemotherapy * No history of rapid disease progression while receiving prior chemotherapy * Measurable disease * Must have less than 25% bone marrow involvement with lymphoma * Prior solid organ transplantation required * Evaluation of malignant cells for Epstein-Barr virus (EBV) required * EBV positive or negative allowed * No pleural effusion * No CNS lymphoma, including leptomeningeal disease * No pulmonary involvement by NHL in patients with prior lung transplantation * No HIV or AIDS-related lymphoma * No hypocellular bone marrow (i.e., less than 15% cellularity) * No marked reduction in bone marrow precursors of one or more cell lines (i.e., granulocytic, megakaryocytic, or erythroid) * Performance status - Karnofsky 50-100% * At least 3 months * Absolute neutrophil count at least 1,500/mm\^3 * Platelet count at least 150,000/mm\^3 * Bilirubin no greater than 2.5 mg/dL * Creatinine no greater than 2.5 mg/dL * Not pregnant or nursing * Negative pregnancy test * Fertile patients must use effective contraception during and for 6 months after study participation * HIV negative * No serious nonmalignant disease or infection that would compromise study objectives * No presence of antimurine antibody reactivity * No other concurrent active malignancy requiring therapy * More than 2 weeks since prior filgrastim (G-CSF) or sargramostim (GM-CSF) * More than 6 weeks since prior rituximab * No prior allogeneic bone marrow or hematopoietic stem cell transplantation * No prior radioimmunotherapy for NHL * More than 4 weeks since prior chemotherapy * See Biologic therapy * No prior radiotherapy to more than 25% of active bone marrow (involved field or regional) * More than 4 weeks since prior major surgery except diagnostic surgery * No other concurrent anticancer therapy